Trial · NCT02192541
Adverse events130
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 130
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Creatinine increased | Investigations | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 0 | 2 | 0 |
| other | Creatinine increased | Investigations | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 2 | 3 | 2 |
| other | Dehydration | Metabolism and nutrition disorders | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 1 | 2 | 1 |
| other | Dehydration | Metabolism and nutrition disorders | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 0 | 3 | 0 |
| other | Dehydration | Metabolism and nutrition disorders | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 0 | 2 | 0 |
| other | Dehydration | Metabolism and nutrition disorders | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 1 | 3 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 1 | 2 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 2 | 3 | 8 |
| other | Diarrhea | Gastrointestinal disorders | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 1 | 2 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 0 | 3 | 0 |
| other | Dizziness | Nervous system disorders | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 0 | 2 | 0 |
| other | Dizziness | Nervous system disorders | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 1 | 3 | 1 |
| other | Electrocardiogram QT corrected interval prolonged | Cardiac disorders | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 1 | 2 | 1 |
| other | Electrocardiogram QT corrected interval prolonged | Cardiac disorders | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 0 | 3 | 0 |
| other | Electrocardiogram QT corrected interval prolonged | Cardiac disorders | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 0 | 2 | 0 |
| other | Electrocardiogram QT corrected interval prolonged | Cardiac disorders | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 1 | 3 | 2 |
| other | Eye infection | Infections and infestations | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 0 | 2 | 0 |
| other | Eye infection | Infections and infestations | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 1 | 3 | 1 |
| other | Fatigue | General disorders | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 1 | 2 | 1 |
| other | Fatigue | General disorders | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 0 | 3 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02192541/events?page=3